Summary
Alzheimer’s Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly. AD is characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities including thinking, language, and learning capacity (National Institute on Aging, 2019). AD is the most common type of dementia (Centers for Disease Control and Prevention, 2019).
The publisher epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for AD was based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Revised (DSM-IV) and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of AD in the 8MM, segmented by age, sex, and severity.
The following data describes epidemiology of AD. In the 8MM, the publisher epidemiologists forecast an increase in the total prevalent cases of AD from 32,753,241 cases in 2018 to 44,473,527 cases in 2028 at an AGR of 3.58% during the forecast period. In the 8MM, the diagnosed prevalent cases of AD will increase from 9,120,848 cases in 2018 to 12,348,971 cases in 2028 at an AGR of 3.54% during the forecast period. AD is more common in older adults. These trends are reflected in the publisher's forecast for the total prevalent cases, and diagnosed prevalent cases for the 8MM.
Scope
The Alzheimer’s disease (AD) Epidemiology Report provides an overview of the risk factors and global trends of AD in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
The report includes a 10-year epidemiological forecast for the prevalent cases of AD (total and diagnosed) segmented by sex, age (ages ≥60 years), and severity in these markets. Additionally, this report provides a 10-year epidemiological forecast for the prevalent cases of mild cognitive impairment (MCI) (total and diagnosed) segmented by sex and age (ages ≥60 years) in these markets.
The AD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to Buy
The Alzheimer’s Disease Epidemiology series will allow you to -
Develop business strategies by understanding the trends shaping and driving the global AD market.
Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
Understand magnitude of AD population by severity at diagnosis.
'
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Alzheimer’s Disease: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for AD (2018-2028)
3.5.1 Total Prevalent Cases of AD
3.5.2 Sex-Specific Total Prevalent Cases of AD
3.5.3 Age-Specific Total Prevalent Cases of AD
3.5.4 Total Prevalent Cases of AD by Severity
3.5.5 Diagnosed Prevalent Cases of AD
3.5.6 Sex-Specific Diagnosed Prevalent Cases of AD
3.5.7 Age-Specific Diagnosed Prevalent Cases of AD
3.5.8 Diagnosed Prevalent Cases of AD by Severity
3.5.9 Total Prevalent Cases of Mild Cognitive Impairment
3.5.10 Sex-Specific Total Prevalent Cases of Mild Cognitive Impairment
3.5.11 Age-Specific Total Prevalent Cases of Mild Cognitive Impairment
3.5.12 Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.5.13 Sex-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.5.14 Age-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - KOLs Interviewed for this Report
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About the Publisher
4.5 Contact
4.6 Disclaimer
